Heron Therapeutics, Inc. (HRTX) Earnings History
Annual and quarterly earnings data from 1989 to 2025
Loading earnings history...
HRTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HRTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 73.3% | -1.6% | -13.0% |
| 2024 | 73.2% | -8.0% | -9.4% |
| 2023 | 48.8% | -87.1% | -87.0% |
| 2022 | 49.0% | -162.2% | -169.1% |
| 2021 | 46.7% | -252.3% | -255.6% |
Download Data
Export HRTX earnings history in CSV or JSON format
Free sign-in required to download data
Heron Therapeutics, Inc. (HRTX) Earnings Overview
As of May 8, 2026, Heron Therapeutics, Inc. (HRTX) reported trailing twelve-month net income of -$20M, reflecting -34.7% year-over-year growth. The company earned $-0.12 per diluted share over the past four quarters, with a net profit margin of -13.0%.
Looking at the long-term picture, HRTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2000.
Heron Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$546M net income, -341.5% margin), PCRX ($9M net income, 1.0% margin), ACRS (-$65M net income, -829.6% margin), HRTX has outperformed on profitability metrics. Compare HRTX vs PACB →
HRTX Earnings vs Peers
Earnings metrics vs comparable public companies
HRTX Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | -48.7% | -$3M | $-0.12 | -13.0% | -1.6% |
| 2024 | -$14M | +87.7% | -$12M | $-0.09 | -9.4% | -8.0% |
| 2023 | -$111M | +39.3% | -$111M | $-0.80 | -87.0% | -87.1% |
| 2022 | -$182M | +17.5% | -$175M | $-1.67 | -169.1% | -162.2% |
| 2021 | -$221M | +2.9% | -$218M | $-2.24 | -255.6% | -252.3% |
| 2020 | -$227M | -11.0% | -$228M | $-2.50 | -256.4% | -257.4% |
| 2019 | -$205M | -14.5% | -$211M | $-2.50 | -140.3% | -144.3% |
| 2018 | -$179M | +9.4% | -$184M | $-2.44 | -230.8% | -237.4% |
| 2017 | -$197M | -14.1% | -$195M | $-3.65 | -641.9% | -632.4% |
| 2016 | -$173M | -77.4% | -$171M | $-4.57 | -13537.4% | -13363.2% |
See HRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRTX — Frequently Asked Questions
Quick answers to the most common questions about buying HRTX stock.
Is HRTX growing earnings?
HRTX EPS fell to $-0.12, with earnings declining -34.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-20M.
What are HRTX's profit margins?
Heron Therapeutics, Inc. net margin is -13.0%, with operating margin at -1.6%. Below-average margins reflect competitive or cost pressures.
How consistent are HRTX's earnings?
HRTX earnings data spans 1989-2025. The declining earnings trend is -34.7% YoY. Historical data enables comparison across business cycles.